Similarly, increased frequencies of PD1+ CD8+ T cells in the TME were associated with better outcomes of PD1 blockade therapies in head and neck cancer [87], NSCLC, and GC [31]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.